FLGR-242

FLGR242

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

An emerging follistatin-associated research construct with very limited compound-specific evidence. Related albumin-binding peptide technology is documented, but FLGR-242 itself does not yet have published human efficacy, safety, or pharmacokinetic data.

Plain English

FLGR-242 is a newer research construct being discussed in the follistatin and muscle-research space. The name and related protein-engineering technology are real, but the science on the exact FLGR-242 product is still extremely limited. Research on follistatin or albumin-binding technology should not automatically be treated as evidence that FLGR-242 works the same way.

Overview

FLGR-242 is an emerging follistatin-associated research construct marketed under the FLGR242 name. Public information links the product concept to recombinant protein and albumin-binding peptide technology, but the precise molecular identity and biological properties of FLGR-242 have not yet been independently established in published compound-specific research. No registered human clinical trial has been identified.

Research Summary

FLGR242 is an emerging research construct associated with follistatin-related protein engineering. A U.S. trademark application for the FLGR242 name was filed in January 2026 for biopharmaceutical preparations involving recombinant protein pharmaceuticals. Separate patent literature from inventor Michael Farber describes albumin-binding peptide constructs using the sequence RLIEDICLPRWGCLWEDD together with glycine-serine linkers. The patented technology is designed to increase albumin binding and extend circulation of attached therapeutic peptides or proteins. Patent documentation also discusses application of this approach to proteins including follistatin. These patents establish the albumin-binding technology and its potential use with protein constructs. They do not establish that every patented construct is FLGR-242, nor do they establish FLGR-242-specific efficacy, safety, or human pharmacokinetics. At the time of review, no FLGR242-specific peer-reviewed human study or registered human clinical trial has been identified. Compound-specific efficacy, safety, dosing, and human half-life therefore remain unestablished.

Research Areas

  • Follistatin research
  • Muscle biology
  • Myostatin-pathway research
  • Protein engineering
United States
Research only; not FDA-approved.
United Kingdom
Research only; current authorization status not established in this record
Australia
Research only; current authorization status not established in this record
Canada
Research only; current authorization status not established in this record

Citations & Sources